申请人:Merck Sharp & Dohme Corp.
公开号:US10189831B2
公开(公告)日:2019-01-29
Compounds of Formula I:
are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
式 I 的化合物:
是 HIV 逆转录酶抑制剂,其中 R1、R2、RE、L、M 和 Z 在本文中定义。式 I 的化合物及其药学上可接受的盐类可用于抑制 HIV 逆转录酶,预防和治疗 HIV 感染,以及预防、延缓艾滋病的发生或发展和治疗艾滋病。这些化合物及其盐类可用作药物组合物的成分,也可与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。